TICKERNERD
Menu
ANTXANTXHealthcare · Biotechnology

ANTX Stock Forecast: AN2 Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$4.40
−5.98% on the day

The 2 Wall Street analysts covering AN2 Therapeutics, Inc. hold a median 12-month price target of $9 — +104.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 9 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$183.0M
Ticker Nerd rank
73 / 100
Median analyst target
$9.00
Analysts covering
2
Revenue$0.0
Operating income−$8.9M
Net income−$8.2M
Free cash flow−$7.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.9%
1M
−23.2%
YTD
+286.0%
1Y
+254.8%
From 52W high
−29.9%
From 52W low
+327.2%
$1.03
$6.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AN2 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Oct 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Revisions
78
Size
70
Quality
62
Value
60
Volatility
58
Accruals
47
Issuance
34
Growth
31

Momentum (95): The shares have been drifting up relative to others.

Growth (31): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26ANTXHigh $9.00Median $9.00Low $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $9.00Median $9.00High $9.00

The green dot is the last close — the median target sits +104.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026GuggenheimInitiatesBuy$9.00
14 May 2026Leerink PartnersUpgradeOutperform$9.00
14 May 2026Leerink PartnersUpgradeOutperform—
5 May 2025JMP SecuritiesMaintainsMarket Outperform—
26 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
25 Feb 2025Citizens Capital MarketsReiteratesMarket Outperform—
3 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
19 Nov 2024JMP SecuritiesReiteratesMarket Outperform—
18 Nov 2024TD CowenDowngradeHold—
9 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
3 July 2024Leerink PartnersUpgradeOutperform—
16 May 2024Evercore ISI GroupMaintainsIn-Line—
2 Apr 2024JMP SecuritiesUpgradeMarket Outperform—
1 Apr 2024OppenheimerReiteratesPerform—
13 Feb 2024Leerink PartnersDowngradeMarket Perform—
12 Feb 2024Evercore ISI GroupDowngradeIn-Line—
12 Feb 2024JMP SecuritiesDowngradeMarket Perform—
12 Feb 2024OppenheimerDowngradePerform—
4 Jan 2024JMP SecuritiesInitiatesMarket Outperform—
30 Mar 2023OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Oct 2026, AN2 Therapeutics, Inc. returned +254.8% against +17.3% for the S&P 500, dividends included.

ANTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26ANTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AN2 Therapeutics, Inc. (ANTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
−3.0×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.1%

Higher than 21% of US stocks

Return on assets
−30.8%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AN2 Therapeutics, Inc. (ANTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AN2 Therapeutics, Inc. has a market value of $183.0M and an enterprise value of $112.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$36.3M.

  • Diluted earnings per share, trailing twelve months: $−1.07.

  • Free cash flow in the twelve months to 30 June 2026: −$30.7M.

  • Shares outstanding: 36.3M.

  • Trailing P/E: −4.2×; forward P/E: −6.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • AN2 Therapeutics, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ANTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANTXAN2 Therapeutics, Inc.$183.0M
73
CHRSCoherus Oncology, Inc.$159.9M
50
NKTXNkarta, Inc.$160.4M
41
MENSJyong Biotech Ltd.$155.9M
3
ABOSAcumen Pharmaceuticals, Inc.$154.5M
43
MDWDMediWound Ltd.$161.9M
28
CNTNCanton Strategic Holdings, Inc.$162.7M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AN2 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANTX news & analysis

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

Business Wire · 28 Sept 2026positive

AN2 Therapeutics announced that the Gates Foundation has awarded an extension of funding to support AN2's research activities under its ongoing tuberculosis research collaboration with GSK, which focuses on developing boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.

Why it matters — The extended Gates Foundation funding provides continued support for AN2's TB collaboration with GSK, helping sustain research progress in its boron chemistry platform.

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

Seeking Alpha · 22 Sept 2026positive

A Seeking Alpha analysis discusses AN2 Therapeutics' epetraborole, which failed in treatment-refractory MAC lung disease but may hold therapeutic potential in polycythemia vera due to its dose-dependent, reversible effects on red-cell parameters. The article highlights supportive human and nonhuman-primate data, with the EBO-PV-201 trial needing to demonstrate hematocrit control, reduced phlebotomy needs, and avoidance of clinically significant anemia.

Why it matters — For ANTX watchers, the article suggests that the previously failed drug epetraborole could become a significant value driver through a potential new indication in polycythemia vera.

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Business Wire · 16 Sept 2026neutral

AN2 Therapeutics announced it granted inducement equity awards to its newly-appointed Chief Medical Officer, Cameron Trenor, M.D., comprising a non-qualified stock option to purchase 233,333 shares of common stock and restricted stock units representing 116,667 shares, under Listing Rule 5635(c)(4).

Why it matters — This announcement reflects the company's recruitment of a new Chief Medical Officer and the standard equity compensation used to secure executive leadership.

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Business Wire · 31 Aug 2026positive

AN2 Therapeutics announced that four abstracts presenting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for polycythemia vera, will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting.

Why it matters — For ANX watchers, this presentation provides new clinical and translational data on the company's lead epetraborole program for polycythemia vera.

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

Business Wire · 24 Aug 2026positive

AN2 Therapeutics announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor brings more than 20 years of experience leading clinical and translational development programs in hematology, rare diseases, and oncology.

Why it matters — This leadership addition brings experienced clinical development expertise to AN2 Therapeutics as it advances its boron chemistry-based small molecule pipeline.

FAQ

Frequently asked questions about ANTX stock

What is the ANTX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering AN2 Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $9 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANTX stock a buy right now?

Of the 2 analysts covering AN2 Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AN2 Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANTX?

As at 9 Oct 2026, AN2 Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will ANTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +104.5% from the last close, and Ticker Nerd's factor model ranks AN2 Therapeutics, Inc. 73 out of 100 as at 9 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANTX stock forecast for 2030?

No analyst covering AN2 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $9 over the next 12 months.

How has ANTX stock performed over the past year?

AN2 Therapeutics, Inc. returned +254.8% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AN2 Therapeutics, Inc. do?

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform.

What is the latest news on ANTX?

The most recent item we track (Business Wire, 28 Sept 2026): "AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK". AN2 Therapeutics announced that the Gates Foundation has awarded an extension of funding to support AN2's research activities under its ongoing tuberculosis research collaboration with GSK, which focuses on developing boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.

Company

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s current pipeline includes programs in infectious diseases, hematologic disorders, and oncology, with research efforts aimed at addressing serious and rare conditions with high unmet medical needs. Its product candidates include oral therapies under development for diseases such as Chagas disease, non-tuberculous mycobacterial lung disease, and other infectious disease targets, alongside earlier-stage oncology and global health programs. AN2 Therapeutics operates as a drug discovery and development business, advancing its candidates through preclinical and clinical studies to support potential future therapies for patients and healthcare providers.

CEO Mr. Eric E. Easom · 21 employees · United States · https://www.an2therapeutics.com